Evofem Biosciences, Inc. (EVFM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Evofem Biosciences, Inc. (EVFM) trades at $0.01 with AI Score 51/100 (Grade B). Evofem Biosciences, Inc. is a biopharmaceutical company focused on women's sexual and reproductive health. Market cap: $1.19M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for EVFM: EVFM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EVFM against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
EVFM: the 1 perspectives are evenly split.
How is this calculated? →Evofem Biosciences, Inc. (EVFM) Healthcare & Pipeline Overview
Evofem Biosciences, Inc. develops and commercializes products for women's sexual and reproductive health, primarily Phexxi, a non-hormonal contraceptive vaginal gel. The company operates in the competitive biotechnology sector, addressing unmet needs in women's health with a focus on innovative solutions.
What Is the Investment Thesis for EVFM?
Evofem Biosciences, Inc. presents a focused investment opportunity within the women's health sector. The primary value driver is the continued adoption and market penetration of Phexxi, the company's non-hormonal contraceptive gel, which caters to a specific segment of women seeking hormone-free options. Growth catalysts include successful clinical trials for EVO100, potentially expanding the product line to address sexually transmitted infections. The company's gross margin of 74.7% indicates strong pricing power. However, potential risks include competition from established contraceptive methods and the challenges of marketing a novel product in a competitive landscape. The company's future success hinges on its ability to effectively commercialize Phexxi and advance its pipeline of product candidates.
Based on FMP financials and quantitative analysis
EVFM Key Highlights
- Phexxi is the company's commercial product, a non-hormonal vaginal gel for contraception.
- EVO100 is an antimicrobial vaginal gel in development for preventing urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections.
- The company's profit margin is 1.9%.
- Gross margin stands at 74.7%, indicating strong pricing power.
- Beta is -1.29, suggesting the stock is less volatile than the market.
Who Are EVFM's Competitors?
EVFM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BAYRY Bayer AG | $14.56 | -4.11% | $57.24B | 51 |
| JNJ Johnson & Johnson | $259.33 | -1.41% | 625B | 90 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 83 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| ABVX Abivax S.A. | $143.99 | -0.46% | 10B | 76 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EVFM's Key Strengths?
- Unique product offering (non-hormonal contraceptive).
- Proprietary technology and patents.
- Focus on unmet needs in women's health.
What Are EVFM's Weaknesses?
- Limited product portfolio.
- Reliance on a single commercial product (Phexxi).
- Small company size and limited resources.
What Could Drive EVFM Stock Higher?
- Clinical trial results for EVO100, potentially expanding the product line to address sexually transmitted infections.
- Continued marketing and sales efforts to increase adoption of Phexxi.
- Potential partnerships with healthcare providers and distributors to expand market reach.
What Are the Key Risks for EVFM?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from established contraceptive methods and other women's health products.
- Regulatory hurdles and delays in the development and approval of new products.
- Reliance on a single commercial product (Phexxi) and the need to diversify revenue streams.
- Financial risks associated with operating in the biotechnology industry, including the need to raise capital to fund research and development.
What Are the Growth Opportunities for EVFM?
- Expansion of Phexxi Market Share: Phexxi's non-hormonal formulation caters to a specific segment of the contraceptive market seeking alternatives to traditional hormonal methods. The addressable market includes women who are hesitant to use hormones or experience adverse side effects. Evofem can increase market share through targeted marketing campaigns, partnerships with healthcare providers, and direct-to-consumer advertising. Success in capturing a larger share of the contraceptive market would drive revenue growth and establish Phexxi as a leading non-hormonal option.
- Successful Development and Commercialization of EVO100: EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections, represents a significant growth opportunity for Evofem. The market for STI prevention is substantial, driven by the increasing prevalence of these infections. Successful clinical trials and regulatory approval of EVO100 would allow Evofem to expand its product portfolio and address a broader range of women's health needs. The timeline for EVO100's development and commercialization depends on the progress of clinical trials and regulatory review.
- Geographic Expansion: Currently, Evofem's primary market is the United States. Expanding into international markets represents a significant growth opportunity. The demand for women's health products is global, and Evofem could leverage its existing product portfolio and expertise to enter new markets. International expansion would require regulatory approvals, distribution agreements, and localized marketing strategies. The timeline for geographic expansion depends on the specific markets targeted and the regulatory landscape in those regions.
- Strategic Partnerships and Acquisitions: Evofem can pursue strategic partnerships and acquisitions to expand its product portfolio, access new technologies, and strengthen its market position. Collaborations with other companies in the women's health sector could accelerate the development and commercialization of new products. Acquisitions of complementary businesses could provide Evofem with access to new markets and customer segments. The timeline for strategic partnerships and acquisitions depends on the availability of suitable targets and the negotiation of mutually beneficial agreements.
- Development of New Formulations and Delivery Systems: Evofem can invest in the development of new formulations and delivery systems for its existing products and pipeline candidates. This could involve exploring new routes of administration, improving the efficacy and safety of existing products, and developing combination therapies. Innovation in formulation and delivery systems could enhance the value proposition of Evofem's products and create new market opportunities. The timeline for the development of new formulations and delivery systems depends on the complexity of the research and development process.
What Opportunities Does EVFM Have?
- Expansion into new markets and geographies.
- Development of new products and indications.
- Strategic partnerships and collaborations.
What Threats Does EVFM Face?
- Competition from established contraceptive methods.
- Regulatory hurdles and delays.
- Product liability risks.
What Are EVFM's Competitive Advantages?
- Proprietary Products: Evofem's products, such as Phexxi, are protected by patents, providing a degree of exclusivity.
- First-Mover Advantage: Phexxi is one of the first non-hormonal contraceptive gels on the market, giving Evofem a first-mover advantage.
- Brand Recognition: Evofem is building brand recognition through its marketing efforts and partnerships with healthcare providers.
What Does EVFM Do?
Evofem Biosciences, Inc. is a biopharmaceutical company dedicated to addressing unmet needs in women's sexual and reproductive health. The company's flagship product is Phexxi, a non-hormonal vaginal gel approved for the prevention of pregnancy. Unlike traditional hormonal contraceptives, Phexxi offers women a hormone-free option. Evofem is also developing EVO100, an antimicrobial vaginal gel designed to prevent urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections. Founded with the mission of empowering women to take control of their reproductive health, Evofem has focused on developing innovative solutions that address specific concerns and preferences. The company's commercial strategy involves direct-to-consumer marketing and partnerships with healthcare providers to increase awareness and adoption of Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California, and operates primarily in the United States. The company aims to expand its product portfolio and market reach to address a broader range of women's health issues.
What Products and Services Does EVFM Offer?
- Develop and commercialize products for women's sexual and reproductive health.
- Offer Phexxi, a non-hormonal vaginal gel for contraception.
- Develop EVO100, an antimicrobial vaginal gel for preventing urogenital infections.
- Conduct clinical trials to evaluate the safety and efficacy of its products.
- Seek regulatory approvals from the FDA and other regulatory agencies.
- Market and distribute its products through healthcare providers and direct-to-consumer channels.
How Does EVFM Make Money?
- Develops and patents proprietary pharmaceutical products.
- Generates revenue through the sale of Phexxi.
- Outsources manufacturing to contract manufacturers.
- Markets and sells products through a combination of direct-to-consumer advertising and partnerships with healthcare providers.
What Industry Does EVFM Operate In?
Evofem Biosciences, Inc. operates within the women's health segment of the biotechnology industry. The market for women's health products is substantial, driven by increasing awareness and demand for innovative solutions. The contraceptive market, in particular, is characterized by a mix of established hormonal methods and emerging non-hormonal options. Evofem's Phexxi competes with established players in the contraceptive market, offering a unique value proposition for women seeking hormone-free alternatives. The company also faces competition from other companies developing treatments for sexually transmitted infections.
Who Are EVFM's Key Customers?
- Women seeking non-hormonal contraception options.
- Healthcare providers who prescribe or recommend contraception to their patients.
- Pharmacies and distributors that stock and sell Evofem's products.
Company Profile
Evofem Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Saundra Pelletier. EVFM has traded publicly since 2014.
F-Score 3/9Financial Health
Evofem Biosciences, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE 9%Key Financial Metrics
Return on equity for Evofem Biosciences, Inc. stands at 8.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -81.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -21.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.08 means current liabilities exceed short-term assets, a liquidity point worth watching.
EVFM Valuation & Market Position
With a $1.19M market cap, Evofem Biosciences, Inc. sits in the micro-cap segment of the market. Relative to its peer group, EVFM's quantitative score of 51/100 is below the peer average of 76/100.
FY2026 estForward Outlook
Wall Street analysts project Evofem Biosciences, Inc. revenue of about $241.1M for fiscal 2026, with EPS near $57.50.
EVFM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Evofem's future, indicating that executives believe in the company's potential.
- Community sentiment has turned positive as discussions around their innovative products gain traction, reflecting growing interest.
- Analysts have highlighted the unique market position of Evofem, especially in women's health, which could lead to increased demand.
- Recent partnerships and collaborations have sparked optimism about the company's ability to expand its market reach.
Bear Case
- Concerns about regulatory hurdles persist, with some investors worried about the approval timeline for new products.
- The market remains cautious due to the company's past financial struggles, leading to skepticism about its long-term viability.
- Negative sentiment has emerged from discussions highlighting potential competition that could impact Evofem's market share.
- Recent earnings reports have raised red flags, with some analysts questioning the sustainability of its current business model.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EVFM Latest News
-
HUB Cyber Security Acquires Certain Senior Subordinated Convertible Notes And Purchase Rights Of Evofem Biosciences In Exchange Solely For HUB Equity Securities
benzinga · Jul 1, 2026
-
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
businesswire.com · May 18, 2026
-
Evofem Biosciences Q1 EPS $(0.04), Sales $899.000K Up From $845.000K YoY
benzinga · May 15, 2026
-
Stocks That Hit 52-Week Highs On Monday
· Dec 2, 2019
EVFM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EVFM.
Price Targets
Wall Street price target analysis for EVFM.
EVFM MoonshotScore
What does this score mean?
The MoonshotScore rates EVFM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
HUB Cyber Security Acquires Certain Senior Subordinated Convertible Notes And Purchase Rights Of Evofem Biosciences In Exchange Solely For HUB Equity Securities
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
Evofem Biosciences Q1 EPS $(0.04), Sales $899.000K Up From $845.000K YoY
Stocks That Hit 52-Week Highs On Monday
Leadership: Saundra Pelletier
Chief Executive Officer
Saundra Pelletier has served as Chief Executive Officer of Evofem Biosciences since 2014. She has over 25 years of experience in the healthcare industry, with a focus on women's health. Prior to joining Evofem, she held leadership positions at various pharmaceutical and biotechnology companies. Pelletier has a strong track record of successfully developing and commercializing innovative healthcare products. She is a passionate advocate for women's health and is committed to addressing unmet needs in this area.
Track Record: Under Saundra Pelletier's leadership, Evofem Biosciences has achieved several key milestones, including the FDA approval and commercial launch of Phexxi. She has also overseen the development of EVO100 and other pipeline candidates. Pelletier has successfully raised capital to fund the company's operations and growth initiatives. Her strategic vision and leadership have been instrumental in positioning Evofem as a leading player in the women's health sector.
EVFM OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) markets. Companies in this tier often do not meet the minimum financial standards required for listing on major exchanges like the NYSE or NASDAQ. These companies may have limited operating history, be in financial distress, or choose not to comply with the stricter reporting requirements of the major exchanges. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency compared to listed companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and transparency.
- Potential for incomplete or outdated financial information.
- Lower trading volumes and wider bid-ask spreads.
- Higher price volatility and illiquidity.
- Increased risk of fraud or manipulation.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and track record.
- Research the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- FDA approval and commercialization of Phexxi.
- Development of EVO100 and other pipeline candidates.
- Experienced management team with a track record in the healthcare industry.
- Focus on addressing unmet needs in women's health.
EVFM Healthcare Stock FAQ
What does Evofem Biosciences, Inc. do?
Evofem Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing products for women's sexual and reproductive health. Its primary product is Phexxi, a non-hormonal vaginal gel for contraception. The company is also developing EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections. Evofem aims to provide women with innovative solutions that address unmet needs in their reproductive health.
What do analysts say about EVFM stock?
Analyst coverage of Evofem Biosciences, Inc. is limited due to its OTC listing and small market capitalization. Key valuation metrics to consider include revenue growth, gross margin, and cash burn rate. Growth considerations include the successful commercialization of Phexxi and the development of EVO100. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions.
What are the main risks for EVFM?
The main risks for Evofem Biosciences, Inc. include competition from established contraceptive methods, regulatory hurdles and delays, reliance on a single commercial product (Phexxi), and financial risks associated with operating in the biotechnology industry. The company's success depends on its ability to effectively commercialize Phexxi, develop new products, and raise capital to fund its operations. Investors should carefully consider these risks before investing in EVFM.
What revenue streams does Evofem Biosciences, Inc. have in healthcare?
Evofem Biosciences, Inc.'s primary revenue stream is currently derived from the sales of Phexxi, its non-hormonal contraceptive vaginal gel. As of 2026, Phexxi is the sole commercial product generating revenue for the company. The company's revenue is dependent on the adoption and market penetration of Phexxi among women seeking non-hormonal contraception options. Future revenue streams may include sales of EVO100, if it receives regulatory approval, and potential licensing agreements for its products.
How does Evofem Biosciences, Inc. navigate regulatory approval processes?
Evofem Biosciences, Inc. navigates regulatory approval processes by conducting clinical trials to evaluate the safety and efficacy of its products. The company works closely with regulatory agencies, such as the FDA, to ensure compliance with regulatory requirements. Evofem's regulatory strategy involves submitting comprehensive data packages to support its applications for regulatory approval. The company's track record includes the FDA approval of Phexxi. Pending approvals may include EVO100, which is currently in development. Evofem is committed to maintaining high standards of regulatory compliance.
What are the key factors to evaluate for EVFM?
Evofem Biosciences, Inc. (EVFM) holds an AI score of 51/100 (moderate). P/E: 2.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does EVFM data refresh on this page?
EVFM prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EVFM's recent stock price performance?
Evofem Biosciences, Inc. (EVFM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Unique product offering (non-hormonal contraceptive). See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data for listed companies.